{"altmetric_id":984610,"counts":{"readers":{"mendeley":86,"citeulike":0,"connotea":0},"news":{"unique_users_count":1,"unique_users":["medpage_today"],"posts_count":1},"total":{"posts_count":2},"f1000":{"unique_users_count":1,"unique_users":["F1000Prime"],"posts_count":1}},"citation":{"abstract":"To assess the safety, tolerability, and pharmacokinetic and pharmacodynamic effects of the -secretase inhibitor avagacestat in patients with mild to moderate Alzheimer disease (AD).","abstract_source":"pubmed","altmetric_jid":"4f6fa5e63cf058f610005734","authors":["Vladimir Coric","Christopher H. van Dyck","Stephen Salloway","Niels Andreasen","Mark Brody","Ralph W. Richter","Hilkka Soininen","Stephen Thein","Thomas Shiovitz","Gary Pilcher","Susan Colby","Linda Rollin","Randy Dockens","Chahin Pachai","Erik Portelius","Ulf Andreasson","Kaj Blennow","Holly Soares","Charles Albright","Howard H. Feldman","Robert M. Berman"],"doi":"10.1001\/archneurol.2012.2194","first_seen_on":"2012-10-05T19:28:39+00:00","issns":["0003-9942"],"issue":"11","journal":"Archives of neurology (1960. Online)","last_mentioned_on":1443546000,"links":["http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22892585","http:\/\/dx.doi.org\/10.1001\/archneurol.2012.2194"],"pmid":"22892585","pubdate":"2012-11-01T00:00:00+00:00","publisher_subjects":[{"name":"Clinical Sciences","scheme":"era"},{"name":"Neurosciences","scheme":"era"},{"name":"Cognitive Science","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"startpage":"1430","subjects":["neurology"],"title":"Safety and Tolerability of the \u03b3-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease.","type":"article","volume":"69","mendeley_url":"http:\/\/www.mendeley.com\/research\/safety-tolerability-%CE%B3secretase-inhibitor-avagacestat-phase-2-study-mild-moderate-alzheimer-disease"},"altmetric_score":{"score":8,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":8},"context_for_score":{"all":{"total_number_of_other_articles":6766814,"mean":6.1671174057849,"rank":816791,"this_scored_higher_than_pct":87,"this_scored_higher_than":5932281,"rank_type":"exact","sample_size":6766814,"percentile":87},"similar_age_3m":{"total_number_of_other_articles":97120,"mean":5.6473202565924,"rank":11823,"this_scored_higher_than_pct":87,"this_scored_higher_than":85044,"rank_type":"exact","sample_size":97120,"percentile":87},"this_journal":{"total_number_of_other_articles":1351,"mean":5.5148962962963,"rank":206,"this_scored_higher_than_pct":84,"this_scored_higher_than":1138,"rank_type":"exact","sample_size":1351,"percentile":84},"similar_age_this_journal_3m":{"total_number_of_other_articles":38,"mean":7.3605405405405,"rank":11,"this_scored_higher_than_pct":68,"this_scored_higher_than":26,"rank_type":"exact","sample_size":38,"percentile":68}}},"demographics":{"users":{"mendeley":{"by_status":{"Unspecified":1,"Professor > Associate Professor":1,"Librarian":1,"Researcher":25,"Student  > Doctoral Student":6,"Student  > Ph. D. Student":21,"Student  > Postgraduate":7,"Other":2,"Student  > Master":10,"Student  > Bachelor":9,"Lecturer":1,"Professor":2},"by_discipline":{"Medicine and Dentistry":29,"Neuroscience":6,"Chemistry":4,"Social Sciences":2,"Psychology":1,"Agricultural and Biological Sciences":24,"Computer Science":2,"Nursing and Health Professions":1,"Business, Management and Accounting":1,"Biochemistry, Genetics and Molecular Biology":6,"Unspecified":7,"Pharmacology, Toxicology and Pharmaceutical Science":3}}},"geo":{"mendeley":{"US":3,"GB":2,"FR":1,"ES":3}}},"posts":{"f1000":[{"title":"Recommended in F1000 Prime","url":"https:\/\/f1000.com\/prime\/717954993","license":"public","citation_ids":[984610],"posted_on":"2012-10-03T00:00:00+00:00","f1000_classes":[],"f1000_score":"1"}],"news":[{"title":"Secretase Inhibitor Fails in Prodromal Alzheimer's Disease","url":"http:\/\/ct.moreover.com\/?a=22849063934&p=1pl&v=1&x=juartne8egAUodqxFV-PuA","license":"public","citation_ids":[962611,4566802,984610,1647211],"posted_on":"2015-09-29T17:00:00+00:00","summary":"Action Points Note that this randomized trial of patients with prodromal Alzheimer's disease found that a secretase inhibitor was no better than placebo at reducing the incidence of cognitive decline.","author":{"name":"MedPage Today","url":"http:\/\/www.medpagetoday.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/262\/normal\/Screen_Shot_2016-02-09_at_10.51.03.png?1455015082"}}]}}